Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma

Ophthalmic Plastic and Reconstructive Surgery

Volumn 29, Issue 2, 2013, Pages 87-92

  Yin, Vivian ^a   Pfeiffer, Margaret ^a   Esmaeli, Bita ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMIQUIMOD; VISMODEGIB;

ACNE; ADVANCED CANCER; ALOPECIA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER SIZE; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG ERUPTION; DYSGEUSIA; DYSPEPSIA; EYE CANCER; EYELID; FATIGUE; GENE MUTATION; HEAD AND NECK CANCER; HEDGEHOG; HUMAN; LEG CRAMP; LESIONS AND DEFECTS; LOW BACK PAIN; LUNG NON SMALL CELL CANCER; LYMPH NODE; METASTASIS; NAUSEA; PANCREAS CANCER; PATCHED 1 GENE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GENE; WEIGHT REDUCTION;

ADULT; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; EYELID NEOPLASMS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; ORBITAL NEOPLASMS; PYRIDINES; SKIN NEOPLASMS;

EID: 84875226599     PISSN: 07409303     EISSN: 15372677     Source Type: Journal    
DOI: 10.1097/IOP.0b013e3182831bf3     Document Type: Review

References (44)

1. Slutsky JB, Jones EC. Periocular cutaneous malignancies: A review of the literature. Dermatol Surg 2012;38:552-69
2. Southwick GJ, Schwartz RA. The basal cell nevus syndrome: Disasters occurring among a series of 36 patients. Cancer 1979;44:2294-305
3. Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg 2011;30(4 suppl):S14-8
4. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59(2 suppl):21-6
5. Farndon PA, Del Mastro RG, Evans DG, et al. Location of gene for Gorlin syndrome. Lancet 1992;339:581-2
6. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841-51
7. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668-71
8. Barnes EA, Heidtman KJ, Donoghue DJ. Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC. Oncogene 2005;24:902-15
9. Ingham PW, McMahon AP. Hedgehog signaling in animal development: Paradigms and principles. Genes Dev 2001;15:3059-87
10. Chen Y, Struhl G. Dual roles for patched in sequestering and transducing Hedgehog. Cell 1996;87:553-63
11. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-2
12. Bonifas JM, Pennypacker S, Chuang PT, et al. Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol 2001;116:739-42
13. Duman-Scheel M, Weng L, Xin S, et al. Hedgehog regulates cell growth and proliferation by inducing cyclin D and cyclin E. Nature 2002;417:299-304
14. Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001;7:706-11
15. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-A potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009;19:5576-81
16. Low JA, de Sauvage FJ. Clinical experience with hedgehog pathway inhibitors. J Clin Oncol 2010;28:5321-6
17. Stanton BZ, Peng LF. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst 2010;6:44-54
18. Tang T, Tang JY, Li D, et al. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res 2011;17:3378-87
19. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11
20. Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:5774-82
21. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72
22. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-9
23. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997;69:299-308
24. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8
25. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37
26. Ivan D, Prieto VG, Esmaeli B, et al. Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma. J Cutan Pathol 2010;37:231-6
27. Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFRtargeted therapy. Pathol Res Pract 2011;207:337-42
28. Maubec E, Duvillard P, Velasco V, et al. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005;25(2B):1205-10
29. Ch'ng S, Low I, Ng D, et al. Epidermal growth factor receptor: A novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol 2008;39:344-9
30. Shimizu T, Izumi H, Oga A, et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology (Basel) 2001;202:203-6
31. Shepler TR, Prieto VG, Diba R, et al. Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthal Plast Reconstr Surg 2006;22:113-5
32. Fan Z, Masui H, Altas I, et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993;53:4322-8
33. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29:3419-26
34. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54
35. Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 2012;18:1435-46
36. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57: 4838-48
37. Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: Efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010;5:1616-22
38. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79
39. Lane K, Goldstein SM. Erlotinib-Associated trichomegaly. Ophthal Plast Reconstr Surg 2007;23:65-6
40. Márquez G, Herrera-Acosta E, Vidal I, et al. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). Int J Dermatol 2009;48:97-8
41. Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 2007;23:63-5
42. Engelhardt C, Curiel-Lewandrowski C, Warneke J, et al. Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy. J Am Acad Dermatol 2011;65:237-8
43. Read WL. Squamous carcinoma of the skin responding to erlotinib: Three cases. J Clin Oncol 2007;25:1651-9
44. El-Sawy T, Sabichi AL, Myers JN, et al. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol 2012;130:1608-11